The SGLT-2 inhibitor canagliflozin has been shown to reduce interleukin-6 (IL-6) levels compared to sulphonyl urea (glimepiride) in patients with type 2 diabetes, but a trend towards a decrease in C-reactive protein (CRP) levels in the canagliflozin group did not reach statistical significance [10]. This evidence concerns the gene IL6 and type 2 diabetes mellitus.